Supplementary Appendix
|
|
- Bernard Mathews
- 6 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367: DOI: /NEJMoa (PDF updated January 3, 2013.)
2 Supplementary Appendix Supplement to: Flaherty KT, Infante JI, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Contents Acknowledgments page 2 Supplementary methods page 2 Supplementary figure 1 page 6 Supplementary figure 2a page 7 Supplementary figure 2b page 8 Supplementary figure 3 page 9 Supplementary figure 4 page 10 Supplementary table 1 page 11 Supplementary table 2 page 12 Supplementary table 3 page 13 Supplementary table 4 page 14 Supplementary table 5 page 15 1
3 Acknowledgements We also thank our investigators and study staff who contributed to the study (listed in alphabetical order by country): Australia: Ludwig Institute for Cancer Research, Austin Hospital- Miles Andrews; Westmead-Arthur Clements, the staff of Sydney West Cancer Trials Centre, and the Surgical, Dermatology and Anatomical Pathology staff of Westmead Hospital and Melanoma Institute Australia; USA: University of Pennsylvania Abramson Cancer Center- Ravi Amaravadi, Lydia Giles; Vanderbilt University- Kristin Ancell; Angeles Clinic- Peter Boasberg; U.T. MD Anderson Cancer Center- Wen-Jen Hwu; University of Colorado Denver-Amanda Iman; University of California San Francisco- Andrea Kantor; Massachusetts General Hospital- Donald Lawrence; Mayo Clinic- Robert McWilliams; Sarah Cannon Research Institute/Tennessee Oncology- Salah Nabhan; Dana Farber Cancer Institute- Geoffrey Shapiro; Johns Hopkins Sidney Kimmel Cancer Center at Green Spring Station- William Sharfman; Yale Medical Center- Mario Sznol; Moffitt Cancer Center- Patricia Urbas. Supplementary methods Eligibility Brain metastases were considered stable if they met the following criteria: asymptomatic with no corticosteroids and/or enzyme-inducing anticonvulsants for 30 days, confirmed stable with two consecutive magnetic resonance imaging (MRI) or computed tomography (CT) scans 90 days apart, and previously treated with surgery or stereotactic radiosurgery; those with untreated brain metastases were excluded. 2
4 Patients with a history of cardiovascular or interstitial lung disease and evidence or risk of retinal vein occlusion or central serous retinopathy were also excluded. Assessments A baseline disease assessment, using CT scan or MRI of chest, abdomen and pelvis, was performed and repeated every 8 weeks. Responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST; 1.1). Adverse events, graded using the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0), were assessed throughout the study and for 14 days after treatment was discontinued. Demographic data and disease characteristics were recorded at baseline. Patients also underwent a physical examination, which included electrocardiogram (ECG) and echocardiogram (ECHO), and ophthalmologic evaluation at baseline. In addition, patients vital signs and ECOG-PS were recorded at this time. Physical examinations and assessment of ECOG-PS were repeated at every cycle, ECG and ECHO assessments were repeated at Week 4, and then every 12 weeks, while ophthalmologic evaluations were repeated as clinically indicated. Chemistry and hematology were assessed every 4 weeks. A baseline disease assessment, using CT scan or MRI of chest, abdomen and pelvis, was performed and repeated every 8 weeks. Responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST; 1.1). Adverse events, graded using the Common Terminology Criteria for Adverse Events 3
5 (CTCAE; version 4.0), were assessed throughout the study and for 14 days post treatment. Pharmacokinetics Samples for PK analyses were obtained at timed intervals up to 24 hours after a single dose of dabrafenib on Day 1 and with trametinib on Day 15 in Part A; on Day 15, or Day 21 using serial samples up to 8 hours post-dose in Part B; and pre-dose on Day 15, and then every 8 weeks in Part C. Plasma concentrations of dabrafenib and its metabolites, and trametinib were analyzed using validated methods. Statistical methods PFS was defined as the time from first dose (Part B) or randomization (Part C) to the first documented radiological progression or death, based on investigator assessment. PFS and OS were estimated using the Kaplan Meier method and comparisons utilized a log-rank test. RR and duration of response are reported for each treatment group, along with the 95% confidence interval (CI), and between-group comparisons were conducted. Safety analyses included all patients who had received 1 dose of study medication and are summarized by frequency and proportion of the total population. Serious adverse events and those leading to treatment discontinuation are summarized separately. Study Oversight This study (NCT ) was funded, administrated, and sponsored by GlaxoSmithKline. The original protocol was designed by Keith Flaherty, M.D. and the 4
6 sponsor. The sponsor collected and analyzed the data and vouches for such data and analysis. All authors had access to all study data. The lead authors (K.T.F., J.R.I., and J.W.) developed the first draft of the manuscript in collaboration with the sponsor. All authors reviewed subsequent drafts and are responsible for the decision to publish. 5
7 Supplemental Figure 1 - CONSORT diagram * * One patient was randomized to dabrafenib monotherapy but received 150/2 combination. As a result, a total of 55 subjects received combination 150/2 in Part C 6
8 Supplemental Figure 2a - Dabrafenib Pharmacokinetics in Part B Patients 7
9 Supplemental Figure 2b - Trametinib Pharmacokinetics in Part B Patients 8
10 Supplemental Figure 3 - Overall Survival in Part C 9
11 Supplemental Figure 4 - Independent Review Committee Assessed Progression Free Survival in Part C 10
12 Supplementary Tables Table S1. Part C - Study medication exposure, dose interruptions, and dose reductions Part C/randomized Phase II (n=162) Dabrafenib Monotherapy (n=53) Combination 150 mg/1 mg (n=54) Combination 150mg/ 2 mg (n=55) Exposure Median duration on study treatment, months (min, max) 6.1 (1.8, 15.2) 10.5 (0.9, 16.4) 11.0 (2.1, 17.3) Dose Interruptions due to toxicity any dose interruption, n (%) 15 (28) 32 (59) 37 (67) dabrafenib dose interruption, n (%) 15 (28) 31 (57) 34 (62) trametinib dose interruption, n (%) NA 29 (54) 35 (64) Dose Reductions due to toxicity any dose reduction 10 (19) 27 (50) 32 (58) dabrafenib dose reduction, n (%) 10 (19) 27 (50) 30 (55) re-escalation, n(%)* 9 (90) 20 (74) 28 (93) trametinib dose reduction, n (%) NA 1 (2) 12 (22) re-escalation, n(%)** NA 0 4 (33) * For percentage calculation, the denominator is the number of subjects with dabrafenib reduction. ** For percentage calculation, the denominator is the number of subjects with trametinib dose reduction. One subject was randomized to dabrafenib monotherapy but received combination 150/2. This subject was included in combination 150/2 safety analyses. 11
13 Table S2. Part A - Assessment of repeat-dose trametinib on single-dose dabrafenib pharmacokinetics Dabrafenib PK parameter Number of patients (Day 1/Day 15) Geometric Least-Squares Mean Ratio for Day 15/Day 1 (90% CI) AUC (0-t) (ng.hr/ml) 8/ (0.85, 1.19) AUC (0-inf) (ng.hr/ml) 7/ (0.82, 1.08) C max (ng/ml) 8/ (0.79, 1.34) 12
14 Table S3. Parts A and B - Patient characteristics at baseline Characteristic Parts A and B* (n=85) All doses Median age, years (range) 52.8 (25-80) Male gender, n (%) 53 (62%) White race, n (%) 83 (98%) ECOG performance status, n (%) 0 1 M status, n (%) M0 M1a M1b M1c 45 (53%) 40 (47%) 0 6 (7%) 11 (13%) 68 (80%) Disease sites 3, n (%) 60 (71%) History of brain metastases, n (%) 22 (26%) LDH > upper limit of normal, n (%) 41 (48%) BRAF mutation status, n (%) V600E V600K 77 (91) 7 (8) Previous chemotherapy, n (%) 49 (58%) Previous immunotherapy, n (%) 26 (31%) *Other patients included in Part B (dose escalation) were: BRAF inhibitor-treated melanoma (n=26), colorectal (n=28), other tumor types (n=4, 1 non-small cell lung, 1 thyroid, 1 salivary ductal carcinoma, and 1 large cell neuroendocrine carcinoma). One patient in Part A/B was V600R. 13
15 Table S4. Part B - Summary of efficacy endpoints 75 mg BID/ 1 mg QD (n=6) 150 mg BID/ 1 mg QD (n=22) 150 mg BID/ 1.5 mg QD (n=25) 150 mg BID/ 2 mg QD (n=24) Median PFS, months (95% CI) 8.7 (5.3,16.6) 8.2 (5.4, 11.0) 5.4 (3.5, 12.8) 10.8 (5.3, 14.4) PFS rate at 12 months, % (95% CI) 33 (5, 68) 27 (11, 46) 32 (15, 50) 44 (24, 63) Best Response, months (%) Complete Response (CR) 0 4 (18) 0 2 (8) Partial Response (PR) 4 (67) 10 (45) 11 (44) 13 (54) Stable Disease (SD) 2 (33) 7 (32) 11 (44) 9 (38) Non-CR/Non-PD (4) 0 Progressive Disease (PD) 0 1 (5) 2 (8) 0 Response Rate CR+PR (%) 4 (67) 14 (64) 11 (44) 15 (63) 95% CI 22.3, , , , 81.2 Median Duration of Response, months (95% CI) 12.4 (3.7, 14.9) 8.4 (5.5, NA) 12.6 (6.5, NA) 11.3 (9.1, 16.9) 14
16 Table S5. Part B - Adverse events in >20% regardless of causal relationship 75 mg BID/ 1 mg QD (n=6) 150 mg BID/ 1 mg QD (n=22) 150 mg BID/ 1.5 mg QD (n=25) 150 mg BID/ 2 mg QD (n=24) Grade 3/4 Total Grade 3/4 Total Grade 3/4 Total Grade 3/4 Total Any event 3 (50) 6 (100) 13 (59) 22 (100) 12 (48) 25 (100) 12 (50) 24 (100) Pyrexia 0 4 (67) 1 (5) 12 (55) 1 (4) 13 (52) 2 (8) 21 (88) Chills 1 (17%) 3 (50) 1 (5%) 10 (45) 0 10 (40) 1 (4) 18 (75) Fatigue 0 4 (67) 2 (9) 12 (55) 2 (8) 12 (48) 1 (4) 13 (54) Headache 0 3 (50) 0 10 (45) 0 7 (28) 0 11 (46) Nausea 0 2 (33) 1 (5) 9 (41) 0 10 (40) 0 10 (42) Cough 0 3 (50) 0 3 (14) 0 9 (36) 0 10 (42) Rash 0 2 (33) 0 4 (18) 0 8 (32) 0 10 (42) Vomiting 0 2 (33) 1 (5) 6 (27) 0 8 (32) 1 (4) 9 (38) Diarrhea 0 2 (33) 2 (9) 9 (41) 0 6 (24) 0 9 (38) Arthralgia 1 (17) 2 (33) 0 4 (18) 1 (4) 4 (16) 0 9 (38) Acneiform dermatitis (5) 0 3 (12) 0 8 (33) Night sweats 0 1 (17) 0 3 (14) 0 6 (24) 0 7 (29) Dizziness 0 1 (17) 0 3 (14) 0 4 (16) 0 7 (29) Constipation 0 1 (17) 0 6 (27) 0 5 (20) 0 6 (25) Edema peripheral (23) 0 5 (20) 0 6 (25) Decreased appetite 0 3 (50) 0 1 (5) 0 4 (16) 0 6 (25) Pain in extremity 0 1 (17) 0 4 (18) 0 1 (4) 0 5 (21) 15
17 Ejection fraction decreased (5) 0 1 (4) 0 5 (21) Oropharyngeal pain (5) 0 1 (4) 0 5 (21) Anaemia (18) 1 (4) 2 (8) 1 (4) 5 (21) Abdominal pain 0 2 (33) 1 (5) 4 (18) 1 (4) 2 (8) 0 3 (13) Asthenia (9) 6 (27) 1 (4) 4 (16) 0 2 (8) Rash generalized 1 (17) 2 (33) 0 3 (14) (4) Pain 0 2 (33) 0 2 (9) 0 2 (8) 0 0 Vision blurred 0 2 (33) 0 3 (14) 0 2 (8)
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Part A Part B Part C
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationTitle A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma
Sponsor Novartis Generic Drug Name Panobinostat Therapeutic Area of Trial Refractory cutaneous T-Cell lymphoma Approved Indication Investigational drug Protocol Number CLBH589B2201 Title A Phase II study
More informationLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationEfficacy of anti-pd-1 therapy in patients with melanoma brain metastases
Efficacy of anti-pd-1 therapy in patients with melanoma brain metastases John J. Park 1, Sagun Parakh 2,3,4, Shehara Mendis 5, Rajat Rai 6, Wen Xu 7, Serigne Lo 6, Martin Drummond 6, Catherine Rowe 7,
More informationInitial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma
Initial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma Reinhard Dummer, 1 Caroline Robert, 2 Marta Nyakas, 3 Grant McArthur,
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Trametinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Protocol Code Tumour Group Contact Physician USMAVDT Skin and Melanoma Dr.
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationSupplementary Online Content
Supplementary Online Content Jänne PA, van den Heuvel MM, Barlesi F, et al. Effect of selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRASmutant
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationSubject: Cobimetinib (Cotellic ) Tablet
09-J2000-53 Original Effective Date: 03/15/16 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Cobimetinib (Cotellic ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOutcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors Allison Ackerman, MD, PhD 1 ; Oliver Klein, MD 2 ; David F. McDermott, MD 1 ; Wei Wang, PhD 3
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationOverall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib () or ENCO in BRAF-Mutant Melanoma, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala,
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationSupplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation
Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation Cohort Dose and Frequency Age and Sex Tumor Type Number of Cycles Best Overall Response 4M Colorectal cancer -
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015 ClinicalTrials.gov ID: NCT01378962 Study Identification Unique Protocol ID: ML25514 Brief Title: A Study
More informationStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)
A service of the U.S. National Institutes of Health Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials Trial
More informationASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018
ASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the Private
More informationClinicalTrials.gov Identifier: NCT Adi Diab 1, Nizar Tannir 1, Daniel Cho
Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma,
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationPRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. ATC Code: L01XE23 Protein Kinase Inhibitor
PRODUCT MONOGRAPH Pr MEKINIST Trametinib Tablets 0.5 mg and 2 mg ATC Code: L01XE23 Protein Kinase Inhibitor Novartis Pharmaceuticals Canada Inc. Date of Revision: 385 Bouchard Blvd. September 21, 2018
More informationONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSynopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02
Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationA First-in-class Phase 1 Dose-escalation Study of the Novel Oral ERK 1/2 Kinase Inhibitor BVD-523 (ulixertinib) in Patients with Advanced Solid Tumors
A First-in-class Phase 1 Dose-escalation Study of the Novel Oral ERK 1/2 Kinase Inhibitor BVD-523 (ulixertinib) in Patients with Advanced Solid Tumors Jeffrey R. Infante, Filip Janku, Anthony W. Tolcher,
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationPrincipal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom
SYNOPSIS Issue Date: 14 October 2010 Document No.: EDMS-ERI-13494974:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: COU-AA-BE Cougar Biotechnology, Inc.
More informationPresented at the 58 th American Society of Hematology Annual Meeting and Exposition, December 5, 2016, San Diego, CA
1070 Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAccrual Status We are currently only enrolling patients who are either:
CC#124522 An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationRandomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) ASCO Annual Meeting 2017 Randomized trial of irinotecan and cetuximab with
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationB. G. Redman University of Michigan, Ann Arbor, MI. J. A. Thompson University of Washington, Seattle, WA
Identification of a well-tolerated outpatient regimen of intravenous recombinant human interleukin-2 (IL-2) in patients with metastatic melanoma and metastatic renal cell carcinoma J. A. Thompson University
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Sutent / Sunitinib
More informationAppendices. Appendix A Search terms
Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.
More informationDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationPRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. Protein Kinase Inhibitor (L01XE23)
PRODUCT MONOGRAPH Pr MEKINIST Trametinib Tablets 0.5 mg and 2 mg Protein Kinase Inhibitor (L01XE23) Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 Date of Revision: May
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationArray BioPharma Jefferies 2016 Global Healthcare Conference. June 9, 2016
Array BioPharma Jefferies 216 Global Healthcare Conference June 9, 216 Safe Harbor Statement 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationASCO Annual Meeting 2013, May 31 June , Chicago, IL
Phase I Study of Safety and Pharmacokinetics of GDC-0917, an Antagonist of Inhibitor of Apoptosis Proteins in Patients with Refractory Solid Tumors or Lymphoma 1 A Tolcher, 1 K Papadopoulos, 1 A Patnaik,
More informationTafinlar. Tafinlar (dabrafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.37 Subject: Tafinlar Page: 1 of 6 Last Review Date: June 19, 2015 Tafinlar Description Tafinlar (dabrafenib)
More informationAt Fox Chase Cancer Centre during study participation
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor Ixazomib at the Recommended Phase 3 Dose in Patients with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis
More informationEfficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
A service of the U.S. National Institutes of Health Trial record 3 of 67 for: BRAF V600E Previous Study Return to List Next Study Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
More informationThe changing landscape of medical management of stage III and IV melanoma Current treatments and what s on the horizon
The changing landscape of medical management of stage III and IV melanoma Current treatments and what s on the horizon Samantha Bowyer Medical Oncologist Rockingham General Hospital Historical perspective
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationSYNOPSIS. Issue Date: 31 July 2013
SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Trametinib (Mekinist) for Metastatic Melanoma October 22, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Trametinib (Mekinist) for Metastatic Melanoma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationModern therapy in oncology Metastatic melanoma
Modern therapy in oncology Metastatic melanoma Anna Buda-Nowak Oncology Department; University Hospital in Cracow Melanoma Malignant skin neoplasm derived from neuroectodermal melanomatous cells. The incidence:
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationProduct: Talimogene Laherparepvec Clinical Study Report: Date: 31 October 2018 Page 1
Date: 31 October 2018 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Imlygic Name of Active Ingredient: Talimogene laherparepvec Title of Study: A Phase
More informationEfficacy of larotrectinib in adolescents and young adults with TRK fusion cancer
Efficacy of larotrectinib in adolescents and young adults with TRK fusion cancer Soledad Gallego, 1 Valentina Boni, 2 Ulrik Lassen, 3 Anna Farago, 4 Wafik El-Deiry, 5 David Hong, 6 Blanca López-Ibor, 2
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationEric Van Cutsem University Hospitals Leuven, Belgium
BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti Epidermal Growth Factor Receptor Antibody Cetuximab for BRAF V600E Metastatic Colorectal
More informationBRAF Inhibition in Melanoma
BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma using vemurafenib and cobimetinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma using vemurafenib and cobimetinib Protocol Code Tumour Group Contact Physician USMAVVC Skin and
More informationMekinist. Mekinist (trametinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.38 Subject: Mekinist Page: 1 of 6 Last Review Date: June 22, 2017 Mekinist Description Mekinist (trametinib)
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More information